---
layout: default
title: Carvedilol
parent: Model Prediction Only (L5)
nav_order: 502
evidence_level: L5
indication_count: 5
---

# Carvedilol
{: .fs-9 }

Evidence Level: **L5** | Predicted Indications: **5** 
{: .fs-6 .fw-300 }

---

## Table of Contents
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## Pharmacist Assessment Report

</div>

# Carvedilol: From Hypertension to Malignant Hypertensive Renal Disease

## One-Sentence Summary

Carvedilol is a marketed beta-blocker with alpha-1 blocking activity, used as a blood pressure-lowering drug.
The TxGNN model predicts it may be effective for **malignant hypertensive renal disease**.
There are currently **0 clinical trials** and **0 publications** supporting this specific prediction, so it is a model-only hypothesis.

## Quick Overview

| Item | Content |
|------|------|
| Original Indication | Hypertension (general antihypertensive use; label indication text is not available in the supplied data) |
| Predicted New Indication | Malignant hypertensive renal disease |
| TxGNN Prediction Score | 99.55% |
| Evidence Level | L5 |
| US Market Status | ✓ Marketed |
| Number of NDAs | 20 (the five listed are all generic ANDAs) |
| Recommended Decision | Hold |

## Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available in the supplied data. Based on general pharmacology, carvedilol is a non-selective beta-blocker with alpha-1 blockade and vasodilatory activity. It lowers blood pressure, so a benefit in kidney injury caused by severe hypertension is biologically plausible. This link is not supported by the supplied data.

Malignant hypertensive renal disease is kidney damage from severely elevated blood pressure. Carvedilol is already used to treat hypertension, so this is closer to an extension within the same drug class than to true repurposing. The very high score (99.55%) reflects model confidence, not clinical proof.

There are practical limits. Malignant hypertension is an emergency usually managed with titratable IV agents, so oral carvedilol is unlikely to be a primary option.

The same model run also predicted four other indications:

- **Malignant renovascular hypertension** (99.55%): the identical score suggests a shared graph neighborhood rather than independent evidence.
- **Pulmonary hypertension, unclear multifactorial mechanism** (99.54%): beta-blockers are used cautiously in pulmonary hypertension because of possible harm to right ventricular function.
- **Pulmonary hypertension owing to lung disease and/or hypoxia** (99.54%): carvedilol is non-selective and can cause bronchospasm in obstructive lung disease.
- **Braddock syndrome** (99.37%): a rare syndrome with no defined link to carvedilol.

All four are L5 with no supporting trials.

## Clinical Trial Evidence

Currently no related clinical trials registered.

## Literature Evidence

Currently no related literature available.

Note: the 20 publications retrieved for the hypoxia-related pulmonary hypertension prediction are generic hypoxia papers (brain aging, cancer, altitude, multiple sclerosis). None mention carvedilol or pulmonary hypertension, so they do not count as evidence.

## US Market Information

| Authorization Number | Product Name | Dosage Form | Manufacturer |
|---------|------|------|-----------|
| ANDA204717 | Carvedilol Phosphate | Extended-release capsule | AvKARE |
| ANDA077614 | Carvedilol | Film-coated tablet | A-S Medication Solutions |
| ANDA078384 | Carvedilol | Film-coated tablet | Golden State Medical Supply, Inc. |
| ANDA077614 | Carvedilol | Film-coated tablet | Northwind Health Company, LLC |
| ANDA078384 | Carvedilol | Film-coated tablet | Golden State Medical Supply, Inc. |

Both dosage forms are oral. Approved indication text was not provided in the data.

## Safety Considerations

Please refer to the package insert for safety information.

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
The prediction score is high, but it is a model output only (L5), with no clinical trials and no drug-specific literature. Malignant hypertension is normally treated with IV agents, and carvedilol is already an established antihypertensive, so the added value is unclear.

**To proceed, the following is needed:**
- Package insert warnings and contraindications (a blocking gap for safety screening)
- Mechanism of action data from DrugBank
- Targeted literature search for carvedilol in hypertensive nephropathy and malignant hypertension
- Clinical rationale for oral carvedilol in an emergency setting where IV therapy is standard
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

